Article and Video CATEGORIES
Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer. Though the field has a lot of intuitive appeal, harnessing the body's own immune system to fight cancer with the hope of sustained effect and a very mild side effect profile, proven benefits of immunotherapy in cancer have been slow to come. But in the last few years, we've seen new treatments with impressive survival benefits in prostate cancer, melanoma, and others...while in lung cancer, the key studies are being conducted but have yet to report out.
Dr. Govindan covered the big topics of MAGE-A3, Stimuvax, and Lucanix in his part of the program. The audio and video versions of the podcast are below, along with the transcript and figures.
Govindan Immunotherapies in LC Part 1 Audio Podcast
Govindan Immunotherapies for LC Part 1 Transcript
Govindan Immunotherapies in LC Part 1 Figs
Part 2, featuring Dr. Brahmer, is being edited now and will be available soon. This includes some discussion of the research into the anti-PD1 vaccine that emerged as one of the most exciting stories in lung cancer from ASCO 2012, so look for that here soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's beautiful Linda. Thank you,